Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
topiramate + aripiprazole
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of topiramate, an anticonvulsant, and aripiprazole, an atypical antipsychotic. Topiramate works by blocking voltage-dependent sodium channels, potentiating GABAergic transmission, and inhibiting excitatory pathways through AMPA receptor sites. Aripiprazole acts as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors, while functioning as an antagonist at 5-HT2A receptors. This combination has been studied for borderline personality disorder, alcohol use disorder, and conditions where metabolic considerations are important.
02
Targets
iGluR (Ionotropic receptor 76b (Ir76b))DRD2 (Dopamine D2 Receptor)GABRR (GABA-A receptor subunit rho)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)AMPAR (AMPA receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on topiramate + aripiprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on topiramate + aripiprazole.